Who: Eli Lilly/Disarm Therapeutics
What: Lilly is making its second acquisition of the year, buying privately held Disarm and its preclinical SARM1 inhibitor
Lilly Tries New Neuro Approach With Disarm Buyout
Deal Snapshot: Lilly bets $135m on biotech’s preclinical SARM1 inhibitor program, seeing potential in peripheral neuropathy and possibly some bigger targets in neurology like MS and ALS.
More from Deals
• By
An ‘historic economic prosperity deal’ does not include the sector.
• By
Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’
• By
Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.
• By
The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.